Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Thermal Enhancement Effect on Chemo-Radiation of Glioblastoma Multiform Publisher



Mahdavi SR1 ; Khalafi L2 ; Nikoofar AR3 ; Fadavi P3 ; Arbabi Kalateh F4 ; Aryafar T5 ; Foudazi H6 ; Mofid B7 ; Sharifi G8 ; Shivaliloo S2 ; Abdollahi H2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Radiation Biology Research Center, Department of Medical Physics, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Physics, School of Medicine (International Campus), Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Roshana radiotherapy and Oncology Center, Tehran, Iran
  5. 5. Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences (International Campus), Tehran, Iran
  6. 6. Omid Radiation Oncology Clinics, Tehran, Iran
  7. 7. Department of Radiation and Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Department of Neurosurgery, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: International Journal of Radiation Research Published:2020


Abstract

Background: Hyperthermia plays a significant role in the chemo-radiotherapy effect in different malignancies. In this research, we treated Glioblastoma multform (GBM) patents with hyperthermia (HT) along with the chemoradiaton, in order to evaluate HT efficacy in terms of tumor volume changes, survival tme, and probability. Materials and Methods: Thirty-eight GBM patents were distributed into two groups identfied as chemoradiaton (CRT), and also CRT plus HT (CRHT). The Karnofsky Performance Status Scale (KPS) was done before, immediately and three months after treatments. Capacitve hyperthermia device was used at frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before the radiotherapy for 10-12 sessions. Patents in both groups underwent MR imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal enhancement factors (TEF) were atained in terms of clinical target volume changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT and CRHT groups, respectvely. For 53% and 47% of cases biopsy and partal resecton were accomplished in both groups, respectvely. Means and standard deviatons of tumor volumes were 135.42±92.5 and 58.4±104.1cm3before treatment in CRT and CRHT groups, respectvely, with no significant difference (P= 0.2). TEF(CTV) value was atained to be as 1.54 and 1.70 for three and six months after treatments, respectvely, TEF(SP) was also equal to the 1.90. Conclusion: HT enhanced the chemoradiaton effects throughout the patent survival probability and KPS. TEF may reflect the hyperthermia efficacy for a given radiaton dose. © 2020 Novin Medical Radiation Institute. All rights reserved.
Related Docs
1. The Epidemiology of Brain and Spinal Cord Tumors, Advances in Experimental Medicine and Biology (2023)
2. Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results From Iran National Cancer Registry, 2010-2014, Journal of Cancer Epidemiology (2020)
3. In Vitro Radiosensitizing Effects of Temozolomide on U87mg Cell Lines of Human Glioblastoma Multiforme, Iranian Journal of Medical Sciences (2017)
4. Preclinical Gene Therapy in Glioblastoma Multiforme: Using Olfactory Ensheathing Cells Containing a Suicide Gene, Life Sciences (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (1)
Mahmoud Reza Hadjighassem (1)